Anti Vegf Eylea 2mg denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti vegf eylea 2mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Eylea (aflibercept 2 mg) as Duplicate Therapy

A duplicate-therapy denial means UnitedHealthcare's system identified another anti-VEGF agent already active on your profile — most commonly a concurrent authorization for bevacizumab, ranibizumab, or another aflibercept formulation — and concluded that dispensing Eylea 2 mg at the same time serves the same clinical purpose. These denials are often administrative rather than clinical: they reflect a coding overlap or an unreversed prior authorization rather than a genuine clinical judgment that the two agents are equivalent for your specific situation.

## Why This Denial Is Appealable

Duplicate-therapy logic assumes the two agents are clinically interchangeable for you. If your prescriber has documented a clinical reason to transition — inadequate response to the prior agent, tolerability issues, treatment-interval goals, or a disease state that the current label specifically addresses — that distinction defeats the duplicate-therapy rationale entirely. The denial is a mechanical flag, not a clinical review.

## Your Federal Appeal Rights

• Internal appeal (Level 1): You have the right to a full internal review under ERISA §503 (employer plans) or your plan's ACA-compliant grievance process. Submit within the timeframe shown on your denial letter — typically 180 days.
• External review (Level 2): Under ACA §2719, if the internal appeal is denied you may escalate to an Independent Review Organization (IRO). Most external reviews must be completed within 45 days; an expedited review (72 hours) is available when the standard timeline would seriously jeopardize your health or your ability to regain maximum function.
• Expedited/concurrent review: If Eylea injections are ongoing and a lapse in therapy would cause clinical harm, request expedited review immediately alongside the internal appeal.

## Documentation to Gather

1. Diagnosis confirmation — chart notes confirming the active retinal diagnosis (e.g., wet AMD, DME, RVO) with the treating ophthalmologist's or retinal specialist's name and dates. 2. Prior-agent history — dates, number of injections, and documented visual acuity or OCT outcomes for every anti-VEGF agent previously or currently authorized, showing why co-administration or sequential use is not equivalent. 3. Clinical necessity letter — a signed letter from your retinal specialist explaining why Eylea 2 mg is the specific agent required now and why the "duplicate" agent does not meet the same clinical need. 4. Active authorization audit — request a printout of every active or pending authorization on your account so you can identify and correct any stale authorizations that triggered the flag. 5. UHC coverage policy — pull UHC's current published medical policy for anti-VEGF agents and confirm which anti-duplication criteria apply; your appeal letter should address each criterion by name.

## Criteria-Mapping Structure for Your Appeal Letter

Copy each requirement listed in UHC's anti-VEGF coverage policy into a two-column table. In the right column, insert the exact chart fact, date, and measurement that satisfies each requirement. For any duplicate-therapy criterion, document the clinical distinction between Eylea 2 mg and the agent already on file. A well-structured criteria map is the single most persuasive element of a first-level appeal and is required for a fair external review record.